Eight telehealth programs scored on the same six-dimension methodology — pricing transparency (25%), clinical oversight (25%), prescriber access (20%), pharmacy transparency (15%), support & operations (10%), trust signals (5%). Our relationship with the #1 pick is disclosed on every page.
Pricing verified July 2026. See the side-by-side comparison.
The list mixes two regulatory categories. Programs like Ro Body, Calibrate, Hims & Hers and Sequence center on brand-name Zepbound/Mounjaro (FDA-approved, generally higher cost, sometimes insurance-assisted). Programs like NexLife, Henry Meds and Mochi center on compounded tirzepatide (cash-pay, lower cost, not FDA-approved). The right choice depends on your insurance, budget, and whether you want a branded product.
Our editor's pick, NexLife, leads on pricing transparency (flat-rate, dose-independent), clinical oversight (MD/DO), and pharmacy transparency (named 503A/503B partners). Read the full NexLife review.